Immunoadsorption of Agonistic Autoantibodies Against α1-Adrenergic Receptors in Patients With Mild to Moderate Dementia

Therapeutic Apheresis and Dialysis

Volumn 20, Issue 5, 2016, Pages 523-529

  Hempel, Petra ^a   Heinig, Bente ^b   Jerosch, Carola ^b   Decius, Imke ^b   Karczewski, Peter ^a   Kassner, Ursula ^b   Kunze, Rudolf ^c   Steinhagen Thiessen, Elisabeth ^b   Bimmler, Marion ^d  

^a ERDE AAB Diagnostics GmbH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Science Office   (Germany)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Autoantibodies; Brain vasculature; Dementia; Immunoadsorption; 1 Adrenergic receptor

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR ANTIBODY; AUTOANTIBODY; UNCLASSIFIED DRUG; ALPHA 1 ADRENERGIC RECEPTOR;

AGED; ALZHEIMER DISEASE; ANTIBODY SCREENING; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOADSORPTION; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PATIENT SAFETY; PRIORITY JOURNAL; DEMENTIA; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME;

AGED; AUTOANTIBODIES; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSORBENT TECHNIQUES; MALE; MIDDLE AGED; RECEPTORS, ADRENERGIC, ALPHA-1; TIME FACTORS; TREATMENT OUTCOME;

EID: 84963957225     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12415     Document Type: Article

References (25)

1. Bickel H. Die Epidemiologie der Demenz. Deutsche Alzheimer-Gesellschaft, Berlin, Germany, 2012.
2. Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer's disease-lessons from pathology. BMC Med 2014;2:206.
3. Doody RS, Thomas RG, Farlow M et al. Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:311–21.
4. Salloway S, Sperling R, Fox NC et al. Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer`s disease. N Engl J Med 2014;370:322–33.
5. Franco R, Cedazo-Minguez A. Successful therapies for Alzheimer's disease: why so many in animal models and none in humans? Front Pharmacol 2014;5:146.
6. de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002;33:1152–62.
7. Marchesi VT. Alzheimer`s disease and CADASIL are heritable, adult-onset dementias that both involve damaged small blood vessels. Cell Mol Life Sci 2014;71:949–55.
8. Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag 2010;6:775–85.
9. Imtiaz B, Tolppanen AM, Kivipelto M, Soininen H. Future directions in Alzheimer's disease from risk factors to prevention. Biochem Pharmacol 2014;88:661–70.
10. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347–51.
11. Tzourio C, Anderson C, Chapman N et al. PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069–75.
12. Saxby BKB, Harrington FM, Wesnes KAP, McKeith IGM, Ford GAM. Candesartan and cognitive decline in older patients with hypertension: A substudy of the SCOPE trial. Neurology 2008;70:1858–66.
13. Jahns R, Boivin V, Hein L et al. Direct evidence for a β1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004;113:1419–29.
14. Dandel M, Wallukat G, Englert A, Hetzer R. Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. Atherosclerosis 2013;14(Suppl):203–11.
15. Wenzel K, Haase H, Wallukat G et al. Potential functional relevance of α1-adrenergic receptor autoantibodies in refractory hypertension. PLoS One 2008;3:e3742.
16. Hempel P, Karczewski P, Kohnert K-D et al. Sera from patients with type 2 diabetes contain agonistic autoantibodies against G protein-coupled receptors. Scand J Immunol 2009;70:159–60.
17. Karczewski P, Hempel P, Kunze R, Bimmler M. Agonistic Autoantibodies to the α1-Adrenergic Receptor and the β2-Adrenergic Receptor in Alzheimer's and Vascular Dementia. Scand J Immunol 2012;75:524–30.
18. Karczewski P, Pohlmann A, Wagenhaus B et al. Antibodies to the alpha1-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography. PLoS One 2012;7:e41602.
19. Klein-Weigel PF, Bimmler M, Hempel P et al. G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger's disease) and their removal by immunoadsorption. Vasa 2014;43:347–52.
20. Wallukat G, Homuth V, Fischer T et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999;103:945–52.
21. Zhou CC, Zhang Y, Irani R et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008;14:855–62.
22. Dragun D, Müller D, Bräsen JH et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005;352:558–69.
23. Zhou Z, Liao Y, Li L et al. Vascular damages in rats immunized by alpha1-adrenoceptor peptides. Cell Mol Immunol 2008;5:349–56.
24. Pohlmann A, Karczewski P, Ku MC et al. Cerebral blood volume estimation by ferumoxytol-enhanced steady-state MRI at 9.4 T reveals microvascular impact of α1-adrenergic receptor antibodies. NMR Biomed 2014;27:1085–93.
25. Boustani M, Peterson B, Harris R et al. Screening for Dementia [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US), 2003(Systematic Evidence Reviews, No. 20.).